Skip to main content Accessibility help
×
Home
  • Print publication year: 2019
  • Online publication date: October 2019

Chapter 21 - Antiseizure Drugs

Summary

In 1857 in England, Charles Locock reported that bromides helped control seizures. Others confirmed this efficacy, and it continued as the only true antiseizure drug (ASD) used chronically until the report of efficacy of phenobarbital (PHB) by Hauptman in 1912. Putnam and Merritt developed phenytoin (PHT) in the 1930s and brought it to market with improved side effects and somewhat greater efficacy than phenobarbital. Carbamazepine (CBZ), chemically unrelated to PHB or PHT but having comparable efficacy, was introduced in the 1960s in Europe, and the United States in the 1970s. Both CBZ and PHT were primarily effective against focal- or partial-onset seizures, with or without associated tonic–clonic attacks. No improvement was noted when used for absence, atonic, tonic, and myoclonic seizures. Ethosuximide was effective for absence seizures, but not focal-onset or tonic–clonic seizures. The introduction of valproate in the 1960s in Europe and in 1978 in the United States dramatically improved the ability to control these seizures. Despite these available antiepileptic drugs, approximately two-thirds of patients did not realize full control. Under the leadership of J. Kiffin Penry, MD, Director of the NIH Epilepsy Branch, and Harvey Kupferberg, PhD, the Antiepileptic Drug Development Program was initiated in a collaborative effort from government, industry, and academia. Since that time many new ASDs have become available. Many brought new mechanisms of action, pharmacokinetic properties, and improved safety or tolerability. Unfortunately, these drugs did not provide greater efficacy in comparative clinical trials than the older standard ASDs, carbamazepine, phenytoin, and valproate. However, in individual cases one of the new ASDs can dramatically improve seizure control, even after many failures with other ASDs.

Related content

Powered by UNSILO
1.Fertig, EJ, Mattson, RH. Carbamazepine. In: Engel, J Jr., Pedley, TA, eds., Epilepsy: A Comprehensive Textbook. Philadelphia: Wolters Kluwer; 2008:15431557.
2.Moseley, B, Kervyn, S, Nicolas, J-M, Stockis, A. A review of the drug-drug interactions of the new antiepileptic drug brivaracetam [abstract]. Neurology. 2017;88(16 Suppl):P4.109.
3.Lattanzi, S, Cagnetti, C, Foschi, N, Provinciali, L, Silvestrini, M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86(14):13441352.
4.Kasteleijn-Nolst, Trenite DG, Genton, P, Parain, D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):10271034.
5.Mattson, RH, Cramer, JA, Collins, JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313(3):145151.
6.Gauthier, AC, Mattson, RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21(7):543548.
7.Wheless, JW, Phelps, SJ. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol. 2013;28(2):219229.
8.Geffrey, AL, Pollack, SF, Bruno, PL, Thiele, EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):12461251.
9.Conry, JA, Ng, YT, Kernitsky, L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014;55(4):558567.
10.Rickels, K, Brown, AS, Cohen, D, et al. Clobazam and diazepam in anxiety. Clin Pharmacol Ther. 1981;30(1):95100.
11.Galiana, GL, Gauthier, AC, Mattson, RH. Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures. Drugs R D. 2017;17(3):329339.
12.Hebeisen, S, Pires, N, Loureiro, AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122135.
13.Bialer, M, Soares-da-Silva, P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935946.
14.Nunes, T, Rocha, JF, Falcao, A, Almeida, L, Soares-da-Silva, P. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54(1):108116.
15.Sperling, MR, French, J, Jacobson, MP, et al. Conversion to eslicarbazepine acetate monotherapy: a pooled analysis of 2 phase III studies. Neurology. 2016;86(12):10951102.
16.Trinka, E, Ben-Menachem, E, Kowacs, PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia. 2018;59(2):479491.
17.Gupta, DK, Bhoi, SK, Kalita, J, Misra, UK. Hyponatremia following esclicarbazepine therapy. Seizure. 2015;29:1114.
18.Glauser, TA, Cnaan, A, Shinnar, S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141155.
19.Livingston, S, Rodriguez, H, Greene, CA, Pauli, LL. Systemic lupus erythematosus: occurrence in association with ethosuximide therapy. JAMA. 1968;204(8):731732.
20.Shi, LL, Dong, J, Ni, H, Geng, J, Wu, T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2011(1):Cd008295.
21.Bonnet, U, Richter, EL, Isbruch, K, Scherbaum, N. On the addictive power of gabapentinoids: a mini-review. Psychiatr Danub. 2018;30(2):142149.
22.Stoehr, T, Freitag, J, Beyreuther, B, et al. (725) Lacosamide has a dual mode of action: selective enhancement of sodium channel slow inactivation [abstract]. J Pain. 2007;8(4 Suppl):S32.
23.Baulac, M, Rosenow, F, Toledo, M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16(1):4354.
24.Kanner, AM, Ashman, E, Gloss, D, et al. Practice guideline update summary. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):7481.
25.Nevitt, SJ, Tudur, Smith C, Weston, J, Marson, AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018;6:CD001031.
26.Gower, AJ, Hirsch, E, Boehrer, A, Noyer, M, Marescaux, C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995;22(3):207213.
27.Brodie, MJ, Perucca, E, Ryvlin, P, Ben-Menachem, E, Meencke, HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402408.
28.Smith, DB, Mattson, RH, Cramer, JA, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia. 1987;28 Suppl 3(s3):S50–58.
29.McLean, MJ, Schmutz, M, Pozza, M, Wamil, A. The influence of rufinamide on sodium currents and action potential firing in rodent neurons [abstract]. Epilepsia. 2005;46(Suppl 8):296.
30.Perucca, E, Cloyd, J, Critchley, D, Fuseau, E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):11231141.
31.Coppola, G, Grosso, S, Franzoni, E, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011;18(2):246251.
32.Kanner, AM, Ashman, E, Gloss, D, et al. Practice guideline update summary. Efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):8290.
33.Privitera, MD, Brodie, MJ, Mattson, RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107(3):165175.
34.Nolan, SJ, Sudell, M, Tudur, Smith C, Marson, AG. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2016;12:CD012065.
35.Baker, GA, Bromley, RL, Briggs, M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84(4):382390.
36.Rey, E, Pons, G, Olive, G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):267278.
37.Xiao, Y, Gan, L, Wang, J, Luo, M, Luo, H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2015(11):CD008781.
38.Baulac, M, Brodie, MJ, Patten, A, Segieth, J, Giorgi, L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11(7):579588.
39.Thiele, EA, Marsh, ED, French, JA et al. Cannabidiol in patients with seizures associated with Lennox–Gastaut skyndrome (GWPCare4): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet, 2018;391:10851096.
40.Devinsky, O, Patel, AD, Cross, JH et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:18881897.
41.Devinsky, O, Cross, JH, Laux, L et al. Trial of cannabidiol in drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017; 376:20112020.
42.American Epilepsy Society Treatments Committee: Vossler, D, Weingarten, M, Gidal, B. Current Review in Clinical Science: Summary of Antiepileptic Drugs Available in the United States of America. July 5, 2018.